氟哌噻吨美利曲辛联合莫沙必利和雷贝拉唑治疗反流性食管炎的效果及对预后生活质量的影响

Effect of Flupentixol-melitracen Combined with Mosapride and Rabeprazole in the Treatment of Reflux Esophagitis and Its Influence on Prognosis and Quality of Life

目的:探讨氟哌噻吨美利曲辛联合莫沙必利和雷贝拉唑对反流性食管炎患者的临床治疗效果及预后生活质量的影响。方法:从本院内一科2017年1月-2018年12月收治的反流性食管炎患者中随机选取50例作为研究对象,按照治疗方式将研究对象分为对照组和观察组,每组25例。对照组患者给予莫沙必利和雷贝拉唑治疗,观察组患者给予氟哌噻吨美利曲辛联合莫沙必利和雷贝拉唑治疗,对比两组患者情绪变化、反流性食管炎各项症状积分、黏膜愈合情况、不良反应发生率及预后生活质量。结果:与治疗前比较,治疗后两组患者焦虑和抑郁情绪均有所改善,差异均有统计学意义(P<0.05);且观察组患者焦虑和抑郁情绪缓解效果均明显优于对照组(P<0.05)。两组患者胃灼热、反流及胸骨后疼痛积分治疗前后对比,差异均有统计学意义(P<0.05);治疗后,观察组患者胃灼热、反流及胸骨后疼痛积分均低于对照组(P<0.05)。治疗后,观察组患者黏膜愈合率为92.00%,对照组为80.00%,两组比较差异有统计学意义(P<0.05)。在治疗过程中观察组患者不良反应发生率为12.00%,对照组为8.00%,两组比较差异无统计学意义(P>0.05)。对照组患者生活质量各项评分均低于观察组,差异均有统计学意义(P<0.05)。结论:反流性食管炎患者给予氟哌噻吨美利曲辛联合莫沙必利和雷贝拉唑治疗,能够有效改善患者的负面情绪,对各项症状的改善作用也较为明显,对食管黏膜具有促进恢复作用,对预后的生活质量具有明显改善作用,在临床上具有较高的推广价值。

Objective:To investigate the clinical curative efficacy and prognostic quality of life of patients with reflux esophagitis treated with Flupentixol-melitracen combined with Mosapride and Rabeprazole.Method:50 patients with reflux esophagitis admitted to department of gastroenterology of our hospital from January2017 to December 2018 were randomly selected as research objects.On the basis of different treatment received,the subjects were divided into control group and observation group 25 cases in each group.Patients in the control group were treated with Mosapride and Rabeprazole,while patients in the observation group were treated with Flupentixol-melitracen combined with Mosapride and Rabeprazole.The emotional changes,scores of various symptoms of reflux esophagitis,mucosal healing,incidence of adverse reactions and prognostic quality of life of two groups were compared.Result:After treatment,the anxiety and depression of two groups were alleviated compared with before treatment,and there were statistical significance(P<0.05),and the levels of reduced anxiety and depression in the observation group were significantly better than those in the control group(P<0.05).The scores of heartburn,reflux and post-sternal pain in two groups were significantly different before and after treatment(P<0.05).After treatment,the scores of heartburn,reflux and post-sternal pain in the observation group were significantly lower than those in the control group(P<0.05).After treatment,the mucosal healing rate of the observation group was 92.00%,and the control group was 80.00%,there was statistical significance(P<0.05).The incidence of adverse reactions in the observation group was 12.00%,and the control group was8.00%,there was no difference between two groups(P>0.05).The scores of qualities of life in the control group were lower than those in the observation group(P<0.05).Conclusion:The treatment of Flupentixol-melitracen combined with Mosapride and Rabeprazole provided for patients with reflux esophagitis can effectively help them deal with their negative emotions,obviously reduce different kinds of symptoms,promote the recovery of esophageal mucosa,improve patients’prognostic quality of life,and has a high value in clinic application.